(Date:11/20/2008)... Plan and Begins Marketing; John Strong, Former Pr...p, Consorta, Inc., to Lead Sales and Marketing Eff...The world,s first permanent international healthca...ess than five years, the key players driving the p...tan tower have been finalized and marketing has be...
(Date:11/20/2008)...nt to lower your risk for type,2 diabetes and hea...g,difference. A study called the Diabetes Prevent...0 percent of your weight can prevent or delay,dis..., 5 percent is just 9,pounds. , In the Uni..., and heart,disease is the leading cause of death...
(Date:11/20/2008)... by HP today announced the winners of its 2008 Vis...th American Exstream User Conference in Cincinnati... (Business Wire EON) November 20, 2008 -- The awa... to make significant strides in improving customer.... Recipients were evaluated on both qualitative an...
(Date:11/20/2008)...wswire/ -- The Gerstman Family was spotlighted on ...rdinary dedication and contribution to physically ...sa Beth Gerstman Foundation. , , Rd.com,s ... those individuals who have made a profound differ...an, co-founder of the Garden City, NY-based Lisa B...
Breaking Medicine News(10 mins):Health News:Permanent International Healthcare Marketplace and Education Center Set to Open in New York City in 2013 2Health News:Permanent International Healthcare Marketplace and Education Center Set to Open in New York City in 2013 3Health News:Permanent International Healthcare Marketplace and Education Center Set to Open in New York City in 2013 4Health News:Permanent International Healthcare Marketplace and Education Center Set to Open in New York City in 2013 5Health News:The 5-Percent Plan: Preventing Diabetes and Heart Disease 2Health News: Exstream Software by HP Announces 2008 Visionary Award Winners : Customers Showcase Innovative Applications Created using the HP Exstream Enterprise Document Automation Solution 2Health News: Exstream Software by HP Announces 2008 Visionary Award Winners : Customers Showcase Innovative Applications Created using the HP Exstream Enterprise Document Automation Solution 3Health News:Gerstman Family Spotlighted on Reader's Digest Website 2(Date:11/20/2008)...RK, Nov. 20 Clinical data from a p...th Annual Veith Symposium shows DVT,treatment wit...acchus,Vascular, Inc. (Santa Clara, CA) successfu...about 20 minutes. , This technique, called ...,blood flow more quickly and safely than current ...
(Date:11/20/2008)...OMSO, Norway, November 20 The Scan...pharma has announced results of studies on its,le...CAAC in Washington, DC,the studies showed that t...bacteriocidal effect, significantly better towards...pyogenes than marketed gold standard drugs. In,ad...
(Date:11/19/2008)...ND OAKS, Calif., Nov. 19 ...da Oncology Company, a subsidiary of,Takeda Pharm...nced that,enrollment in the Phase 3 MONET1 trial ...h paclitaxel and carboplatin for the first-line tr...SCLC) has been temporarily suspended,following a ...
(Date:11/19/2008)...de scientists report basic findings on critical en...w to better treat an array of disorders , , ...- Scientists at St. Jude Children,s Research Hosp...ne of the body,s enzyme workhorses called calpains...s, calpains function in many cellular processes, i...
Breaking Medicine Technology:Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series 2Trellis(R) Peripheral Infusion System Removes Blood Clots in Largest Reported Prospective Endovascular DVT (Deep Vein Thrombosis) Patient Series 3Lytix Presents LTX-109 Anti-Microbial Data at ICAAC 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 3Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 4Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 5Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 6Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 7New Insight Into the Controls on a Go-To Enzyme 2New Insight Into the Controls on a Go-To Enzyme 3Genta Announces Second Quarter 2008 Financial Results and Conference Call 6854 1Genta Announces Second Quarter 2008 Financial Results and Conference Call 6854 2Genta Announces Second Quarter 2008 Financial Results and Conference Call 6854 3Alsius Corporation to Host Second Quarter 2008 Financial Results Conference Call on August 7 6851 1Alsius Corporation to Host Second Quarter 2008 Financial Results Conference Call on August 7 6851 2Cardinal Health Prime Therapeutics Sign Primary Distribution Agreement 6848 1Cardinal Health Prime Therapeutics Sign Primary Distribution Agreement 6848 2Encision Reports First Fiscal Quarter Results 24725 1Encision Reports First Fiscal Quarter Results 24725 2Encision Reports First Fiscal Quarter Results 24725 3Encision Reports First Fiscal Quarter Results 24725 4...Call/ -- Bristol-Myers,Squibb Company (NYSE: BMY) ... showed that treatment with Baraclude (entecavir),...fovir at 48 weeks,-- a result that was also seen a...rom an open-label, randomized viral kinetics study...en (HBeAg),positive patients were presented at the...
.../ -- Data presented,today at a major medical meeti...ts administered once-daily for five days is as,eff...00 mg) for 10,days for the treatment of complicate...ephritis (AP). , Ortho-McNeil, Inc., the company t...ta during a scientific session at the annual,meeti...
Other Medicine Technology:Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 2Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 3Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 4Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 5Baraclude (Entecavir) Treatment Demonstrated Greater Viral Load,Reduction Compared to Adefovir at 48 Weeks in Study of,Antiviral-Naive Chronic Hepatitis B E-Antigen Positive Patients 6Five Days of LEVAQUIN(R) as Effective as 10 Days of Ciprofloxacin,in Complicated Urinary Tract Infections and Acute Pyelonephritis 2Five Days of LEVAQUIN(R) as Effective as 10 Days of Ciprofloxacin,in Complicated Urinary Tract Infections and Acute Pyelonephritis 3Five Days of LEVAQUIN(R) as Effective as 10 Days of Ciprofloxacin,in Complicated Urinary Tract Infections and Acute Pyelonephritis 4This electronic survival guide provides all the essential information that every surgery intern needs from Day 1 on the wards.
The Editors and Contributors are a virtual "Who's Who" in surgery, and they have prepared an outstanding program that provides expert advice on a full range of problems. Destined to be the "gold stan
CURRENT Consult: Surgery brings you authoritative clinical answers on more than 360 surgically treated disorders in the most efficient format, perfectly devised for the busy physician.
Taber's Cyclopedic Medical Dictionary has definitions and information they need to provide care for their patients.
Medicine Products: